Philip Lowry, M.D. '81, named medical ...

Dr. Philip A. Lowry

Claim this profile

Guthrie Medical Group PC-Robert Packer Hospital

Studies Lung Cancer
Studies Breast Cancer
17 reported clinical trials
61 drugs studied

Area of expertise

1

Lung Cancer

Philip A. Lowry has run 5 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage I
Stage III
2

Breast Cancer

Philip A. Lowry has run 5 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage I

Affiliated Hospitals

Image of trial facility.

Guthrie Medical Group PC-Robert Packer Hospital

Image of trial facility.

Guthrie Cancer Center

Clinical Trials Philip A. Lowry is currently running

Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Recruiting

1 award

Phase 2 & 3

13 criteria

Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.

Recruiting

2 awards

Phase 3

23 criteria

More about Philip A. Lowry

Clinical Trial Related

6 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Philip A. Lowry has experience with

  • Nivolumab
  • Ipilimumab
  • Paclitaxel
  • Dabrafenib Mesylate
  • Carboplatin
  • Orelabrutinib (ICP-022)

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Philip A. Lowry specialize in?

Is Philip A. Lowry currently recruiting for clinical trials?

Are there any treatments that Philip A. Lowry has studied deeply?

What is the best way to schedule an appointment with Philip A. Lowry?

What is the office address of Philip A. Lowry?

Is there any support for travel costs?